PRIMARY IMMUNE THROMBOCYTOPENIA
Clinical trials for PRIMARY IMMUNE THROMBOCYTOPENIA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY IMMUNE THROMBOCYTOPENIA trials appear
Sign up with your email to follow new studies for PRIMARY IMMUNE THROMBOCYTOPENIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
ITP drug study halted before it began
Disease control TerminatedThis study was designed to test an experimental drug called HMPL-523 in adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding problems. The goal was to see if the drug is safe and can raise platelet counts. However, th…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE1 • Sponsor: Hutchmed • Aim: Disease control
Last updated May 17, 2026 03:26 UTC
-
New drug shows promise for Long-Term platelet control in rare bleeding disorder
Disease control OngoingThis study tests a drug called efgartigimod in adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. The goal is to see if the drug is safe and helps maintain healthy platelet levels over a year. Partici…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New drug combo aims to extend relief for ITP patients
Disease control OngoingThis study tests whether adding ianalumab to the standard drug eltrombopag can help adults with primary immune thrombocytopenia (ITP) who did not get better or relapsed after steroid treatment. ITP is a condition where the immune system destroys platelets, causing bleeding risks.…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 05, 2026 11:52 UTC